BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 23972713)

  • 21. Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma.
    Santoni M; Heng DYC; Aurilio G; Iozzelli A; Servi L; Fabiani A; Giannini M; Mazzucchelli R; Cimadamore A; Scarpelli M; Zaghloul MS; Battelli N; Montironi R
    Curr Drug Targets; 2020; 21(4):416-423. PubMed ID: 31625471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging immunotherapy in advanced renal cell carcinoma.
    Mendiratta P; Rini BI; Ornstein MC
    Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New agents for the treatment of renal cell carcinoma.
    Tian GG; Dawson NA
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):546-54. PubMed ID: 12113087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?
    Brookman-May S; May M; Gilfrich C; Wieland WF; Burger M
    Expert Rev Anticancer Ther; 2010 Jun; 10(6):813-23. PubMed ID: 20553207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances in immunotherapy for kidney cancer.
    Ball MW; Allaf ME; Drake CG
    Discov Med; 2016 Apr; 21(116):305-13. PubMed ID: 27232516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma.
    Tykodi SS
    Immunotherapy; 2013 Jun; 5(6):607-19. PubMed ID: 23725284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Landscape of Immunotherapy in Genitourinary Malignancies.
    Alhalabi O; Rafei H; Bilen MA; Shah AY
    Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Not Available].
    Vano YA; Simonaggio A; Thibault C; Oudard S
    Bull Cancer; 2018 Dec; 105 Suppl 1():S24-S34. PubMed ID: 30595195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy of renal cell carcinoma.
    Graham SD
    Semin Urol; 1989 Nov; 7(4):215-27. PubMed ID: 2694258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
    Raman R; Vaena D
    Biomed Res Int; 2015; 2015():367354. PubMed ID: 26161397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
    Hutson TE; Quinn DI
    Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New therapeutic developments in renal cell cancer.
    Prenen H; Gil T; Awada A
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring immune therapy for renal cancer.
    Matsushita H; Kakimi K; Tomita Y; Tatsugami K; Naito S; Suekane S; Noguchi M; Moriya F; Matsuoka K; Itoh K; Kobayashi H; Eto M; Takahashi W; Kawano Y; Wada Y
    Int J Urol; 2011 Jun; 18(6):412-21. PubMed ID: 21599759
    [No Abstract]   [Full Text] [Related]  

  • 35. Vaccines in renal cell carcinoma.
    Kübler H; Vieweg J
    Semin Oncol; 2006 Oct; 33(5):614-24. PubMed ID: 17045091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current Immunotherapies for Renal Cell Carcinoma.
    Al-Marrawi MY; Holder SL
    Curr Mol Pharmacol; 2016; 9(3):252-263. PubMed ID: 26177641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma.
    Viey E; Laplace C; Escudier B
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):973-86. PubMed ID: 16336088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoptive cellular therapy.
    Hoffman DM; Gitlitz BJ; Belldegrun A; Figlin RA
    Semin Oncol; 2000 Apr; 27(2):221-33. PubMed ID: 10768601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma.
    Berntsen A; Geertsen PF; Svane IM
    Eur Urol; 2006 Jul; 50(1):34-43. PubMed ID: 16675096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang.
    Ernstoff MS; Crocenzi TS; Seigne JD; Crosby NA; Cole BF; Fisher JL; Uhlenhake JC; Mellinger D; Foster C; Farnham CJ; Mackay K; Szczepiorkowski ZM; Webber SM; Schned AR; Harris RD; Barth RJ; Heaney JA; Noelle RJ
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):733s-740s. PubMed ID: 17255302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.